<SEC-DOCUMENT>0001193125-25-137094.txt : 20250606
<SEC-HEADER>0001193125-25-137094.hdr.sgml : 20250606
<ACCEPTANCE-DATETIME>20250606162356
ACCESSION NUMBER:		0001193125-25-137094
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250606
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250606
DATE AS OF CHANGE:		20250606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phathom Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001783183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				824151574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39094
		FILM NUMBER:		251031058

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(877) 742-8466

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d941196d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:phat="http://www.phathompharma.com/20250606" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-255">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-06-06_to_2025-06-06">0001783183</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="phat-20250606.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-06-06_to_2025-06-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-06</xbrli:startDate> <xbrli:endDate>2025-06-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-266">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt:datemonthdayyearen" id="ixv-267">June 6, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-268">PHATHOM PHARMACEUTICALS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:stateprovnameen" id="ixv-269">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-270">001-39094</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-271">82-4151574</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:99%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-272">100 Campus Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-273">Suite 102</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-274">Florham Park</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:stateprovnameen" id="ixv-275">New Jersey</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-276">07932</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices) (Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-277">(877)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-278">742-8466</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, include area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:boolballotbox" id="ixv-279">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:boolballotbox" id="ixv-280">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:boolballotbox" id="ixv-281">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:boolballotbox" id="ixv-282">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-283">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-284">PHAT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:exchnameen" id="ixv-285">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-06-06_to_2025-06-06" format="ixt-sec:boolballotbox" id="ixv-286">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 6, 2025, Phathom Pharmaceuticals, Inc. (&#8220;Phathom&#8221; or the &#8220;Company&#8221;), announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved the Company&#8217;s Citizen Petition filed on December 11, 2024 (the &#8220;Citizen Petition&#8221;). A copy of the FDA&#8217;s letter approving the Citizen Petition is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The FDA letter can also be found on the FDA&#8217;s website here: https://www.regulations.gov/document/FDA-2024-P-5703-0013. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01, including the exhibits hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the limitations of that section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As referenced above, on June&#160;6, 2025, the FDA has approved the Citizen Petition and communicated its intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA&#174; (vonoprazan) tablets, extending through May&#160;3, 2032. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the timing of the FDA&#8217;s correction to the Orange Book recognizing the Company&#8217;s exclusivity for VOQUEZNA&#174; (vonoprazan) tablets. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in Phathom&#8217;s business, including, without limitation: the timing of the correction to the Orange Book; the expected duration of patent term extension for VOQUEZNA; we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom&#8217;s ability to obtain and maintain intellectual property protection, including patent term extensions, and <span style="white-space:nowrap">non-patent</span> regulatory exclusivity for vonoprazan; Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or <span style="white-space:nowrap">non-patent</span> regulatory exclusivity for VOQUEZNA tablets; Phathom&#8217;s ability to obtain and maintain intellectual property protection and <span style="white-space:nowrap">non-patent</span> regulatory exclusivity for vonoprazan; and other risks described in the Company&#8217;s prior report and the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Report on Form <span style="white-space:nowrap">10-K</span> and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01. Financial Statements and Exhibits. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(d)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d941196dex991.htm">FDA Letter, dated June 6, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">PHATHOM PHARMACEUTICALS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;6, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Basta</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Steven Basta</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President&#160;&amp; Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d941196dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g941196g56z49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terrie Curran </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief
Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phathom Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Campus
Drive, Suite 102 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Florham Park, NJ 07932 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;June&nbsp;6,
 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ms. Curran:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter responds to your citizen petition submitted on behalf of Phathom Pharmaceuticals, Inc. (Phathom), and received on December&nbsp;11, 2024
(Petition). In the Petition, you request that the Food and Drug Administration (FDA or Agency) &#147;correct the publication, <I>Approved Drug Products with Therapeutic Equivalence Evaluations</I> (the &#145;Orange Book&#146;), to accurately reflect
the statutorily-required <FONT STYLE="white-space:nowrap">10-year</FONT> period of <FONT STYLE="white-space:nowrap">non-patent</FONT> new chemical entity (&#145;NCE&#146;) exclusivity&#148; in the Orange Book listing for Voquezna (vonoprazan
fumarate) new drug application (NDA) 215151 (Petition at 1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specifically, Phathom argues that Voquezna should benefit from the NCE and Generating
Antibiotic Incentives Now (GAIN) (NCE*GAIN) exclusivity granted to Voquezna Triple Pak <FONT STYLE="white-space:nowrap">(co-package</FONT> of vonoprazan fumarate, amoxicillin, and clarithromycin) NDA 215152 and Voquezna Dual Pak <FONT
STYLE="white-space:nowrap">(co-package</FONT> of vonoprazan fumarate and amoxicillin) NDA 215153 (collectively, the Voquezna Paks). Vonoprazan, the active moiety first approved in the Voquezna Paks, was recognized as a NCE upon approval. The
Voquezna Paks received qualified infectious disease product (QIDP) designation and, pursuant to the GAIN provisions, the NCE exclusivity recognized for the Voquezna Paks was extended by 5 years, resulting in a total of 10 years of NCE*GAIN
exclusivity with respect to the active moiety vonoprazan. Phathom contends that under FDA&#146;s <I>umbrella policy,</I> this exclusivity should extend to Voquezna because it contains the same active moiety (vonoprazan), despite Voquezna not
independently being designated as a QIDP.<SUP STYLE="font-size:75%; vertical-align:top">1, 2</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FDA has carefully considered the Petition, including
the public comments submitted to the docket. For the reasons described below, the Petition is granted. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term <I>umbrella policy</I> is a term of art that describes FDA&#146;s statutory interpretation of the <FONT
STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity provisions that allows for subsequently approved drug products containing the same new active moiety to benefit from the remainder of the NCE exclusivity for the first approved drug product,
thus allowing all drug products containing the novel active moiety to be protected during the <FONT STYLE="white-space:nowrap">5-year</FONT> period of NCE exclusivity. See section I.B of this response for more details on the umbrella policy.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Phathom did not request QIDP designation for Voquezna NDA 215151. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Food&nbsp;&amp; Drug Administration </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10903 New Hampshire
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silver Spring, MD 20993 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.fda.gov <B></B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL AND REGULATORY BACKGROUND </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">5-year</FONT> NCE Exclusivity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Hatch-Waxman Amendments provide incentives for pharmaceutical innovation in the form of exclusivities, including
<FONT STYLE="white-space:nowrap">5-year</FONT> exclusivity, to protect qualified drugs submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 355(b)) from competition from certain 505(b)(2) NDAs and
abbreviated new drug applications (ANDAs) for varying periods of time depending on the factual circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">5-year</FONT> exclusivity statutory provision provides: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>If an application submitted under subsection
(b)</I><I></I><I>&nbsp;for a drug, no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) of which has been approved in any other application under subsection (b), is
approved after [September 24, 1984]</I><B>, no application which refers to the drug for which the subsection (b)</B><B></B><B>&nbsp;application was submitted and for which the investigations described in subsection (b)(1)(A)(i) and relied upon by
the applicant for approval of the application were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted may be submitted under
subsection (b)</B><B></B><B>&nbsp;before the expiration of five years from the date of the approval of the application under subsection (b), except that such an application may be submitted under subsection (b)</B><B></B><B>&nbsp;after the
expiration of four years from the date of the approval of the subsection (b)</B><B></B><B>&nbsp;application if it contains a certification of patent invalidity or noninfringement described in clause (iv)</B><B></B><B>&nbsp;of subsection
(b)(2)(A).</B><SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this provision, the first clause (italicized text) describes which <I>drugs</I>
are NCEs (eligibility clause), and thus eligible for <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity, and the second clause (bold text) describes the applications that are blocked by such exclusivity (bar clause). The eligibility
clause commands a <FONT STYLE="white-space:nowrap">5-year</FONT> exclusivity period for a drug, &#147;no active moiety . . . of which has been approved in any other application under [section 505(b) of the FD&amp;C Act].&#148; The Agency has
interpreted the term <I>drug</I> in both the eligibility and bar clauses to mean drug substance that contains an active moiety.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a drug has met the requirements of the eligibility clause, the bar clause prevents the submission of any ANDA or 505(b)(2) NDA that &#147;refers to the
<I>drug</I> for which the [505(b)] application was submitted&#148; (emphasis added). This exclusivity generally has been interpreted to prevent an applicant from submitting a 505(b)(2) NDA or ANDA for a drug that contains the same active moiety
approved in the protected drug for a <FONT STYLE="white-space:nowrap">5-year</FONT> period from the date of approval of the protected drug.<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> Five-year NCE exclusivity does not block submission or
review of stand-alone 505(b)(1) NDAs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;505(c)(3)(E)(ii) of the FD&amp;C Act (emphasis added). See also section 505(j)(5)(F)(ii) of the
FD&amp;C Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See section I.B, below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Id. (An applicant may submit a 505(b)(2) NDA or an ANDA after 4 years under specific circumstances described in
sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the FD&amp;C Act that are not at issue here.) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NCE Exclusivity and the Umbrella Policy </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the 1989 proposed rule &#147;Abbreviated New Drug Application Regulations,&#148; the Agency addressed how it would interpret certain statutory exclusivity
provisions, including the <FONT STYLE="white-space:nowrap">5-year</FONT> exclusivity statutory provisions, to operationalize these valuable incentives.<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> The Agency chose an interpretation that
allowed for this exclusivity to protect all drug products containing the novel active moiety during the <FONT STYLE="white-space:nowrap">5-year</FONT> pendency of the exclusivity period under the <I>umbrella</I> of the exclusivity recognized for the
first approval of the novel active moiety. The Agency explained: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The language of sections 505(c)(3)(D) and 505(j)(4)(D) of the [FD&amp;C
Act] is ambiguous as to which ANDAs or 505(b)(2) applications are affected by an innovator&#146;s exclusivity. The statutory language allows at least two interpretations. The narrower interpretation of the protection offered by exclusivity is that
exclusivity covers only specific drug products and therefore protects from generic competition only the first approved version of a drug . . . . Under this interpretation, an innovator&#146;s exclusivity could lose its value as soon as FDA approved
a second full new drug application for a version of the drug, because an ANDA could be approved by reference to the second approved version of the drug, which would not be covered by exclusivity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The broader interpretation of the coverage of exclusivity is that it covers the active moieties in new chemical entities . . . rather than
covering only specific drug products. Thus exclusivity would protect the new active moiety of a new chemical entity . . . from generic competition even after FDA had approved subsequent full new drug applications for subsequent versions of the drug.
Under this theory, an ANDA or 505(b)(2) application for a drug with the same active moiety as the innovator&#146;s new chemical entity . . . could not be approved until the innovator&#146;s exclusivity expired, even if the ANDA or 505(b)(2)
application relied on another approved version of the innovator&#146;s drug.<SUP STYLE="font-size:75%; vertical-align:top">7</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To allow for this
interpretation, FDA explained that the term <I>drug</I> in the bar clause of the <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity provisions meant <I>drug substance.</I><SUP STYLE="font-size:75%; vertical-align:top">8</SUP> Under this
interpretation, now referred to as the umbrella policy, after a drug product becomes eligible for <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity, certain drug products subsequently developed and approved that contain the same active
moiety would also benefit from the original drug product&#146;s <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity until the exclusivity period for the original drug product has
expired.<SUP STYLE="font-size:75%; vertical-align:top">9</SUP> Alternatively said, under the umbrella policy, <FONT STYLE="white-space:nowrap">5-year</FONT> exclusivity attaches to the previously unapproved active moiety, and thus, not only to the
first approved drug product that was eligible for <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity, <B>but also to other drug </B><B>products containing the same active moiety.</B> Thus, the scope of
<FONT STYLE="white-space:nowrap">5-year</FONT> exclusivity is the NCE (new active moiety).<SUP STYLE="font-size:75%; vertical-align:top">10</SUP> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposed rule, &#147;Abbreviated New Drug Application Regulations,&#148; 54 FR 28872 (July 10, 1989) at 28897.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Id. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">54 FR 28872 at 28898&#150;28899. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Id </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">10</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FDA explained this interpretation as follows: &#147;[T]he agency interprets
<FONT STYLE="white-space:nowrap">[5-year</FONT> NCE exclusivity] to cover any subsequent approval of an application or supplemental application for a different ester, salt, or other noncovalent derivative, or a different dosage form, strength, route
of administration, or new use of a drug with the same active moiety. Any modification to the product will be protected for the period of exclusivity remaining on the original application, unless the change occurs after or toward the end of the
initial 5 years of exclusivity and independently qualifies for exclusivity under another exclusivity provision&#148; (54 FR 28872 at 28898&#150;28899). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, under the umbrella policy, <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity will
apply not just to the first approved drug product containing no previously approved active moiety but also to any subsequently approved drug product developed that contains the same new active moiety as in the first drug product and that is approved
during the <FONT STYLE="white-space:nowrap">5-year</FONT> period. Such a subsequently approved drug product will be protected for the balance of the <FONT STYLE="white-space:nowrap">5-year</FONT> period, which runs from the date of approval of the
first approved drug product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The goal of the umbrella policy is to encourage further development and improvement of drug products containing the NCE
without compromising the innovator&#146;s exclusivity period by allowing the innovator to market different drug products containing the same active moiety and to benefit from the <FONT STYLE="white-space:nowrap">5-year</FONT> protection while doing
so. FDA explained its reasoning for adopting the broader interpretation of the coverage of exclusivity as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[I]f FDA adopted the
narrower interpretation that exclusivity covers only a specific drug product and does not prevent ANDAs from copying subsequent versions of the innovative product, a manufacturer of a new chemical entity (entitled to 5 years of exclusivity), could
not make improvements in the drug, e.g., by making a new dosage form of the drug, without destroying the value of its exclusivity. Approval of a new dosage form, and certain other changes in approved drugs, require the submission of a new drug
application; once approved, the new dosage form would become a new drug product that an ANDA application could copy, without being subject to the exclusivity covering the original drug product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the same reasons, an innovator whose drug was entitled to exclusivity could not license another company to make a copy of the pioneer drug
without losing the value of its exclusivity. Under the narrow theory of exclusivity, once the licensed company&#146;s product was approved, ANDA applicants could copy the licensed product, without regard to the innovator&#146;s exclusivity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The agency does not believe that Congress intended the exclusivity provisions to discourage innovators from making improvements in their drug
products nor from authorizing the marketing of competitive products. Accordingly, FDA has concluded that the broader interpretation of the scope of exclusivity should be applied to all types of exclusivity conferred by sections 505(c)(3)(D) and
505(j)(4)(D) of the [FD&amp;C Act].<SUP STYLE="font-size:75%; vertical-align:top">11</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, the umbrella policy is also an important legal and
policy consideration in the Agency&#146;s statutory interpretations regarding the eligibility of <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity for certain fixed-combination drug products containing a new active moiety in combination
with a previously </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">11</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">54 FR 28872 at 28897. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">approved active moiety (or moieties), a fact recognized by Federal courts,<SUP
STYLE="font-size:75%; vertical-align:top">12</SUP> including for fixed-combinations containing old antibiotics in combination with new active moieties (such as the Voquezna Paks). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The GAIN Extension </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;505E of the FD&amp;C Act provides for a <FONT STYLE="white-space:nowrap">5-year</FONT> extension of exclusivity periods upon approval of certain
applications for drug products that have been designated as QIDPs. Specifically, section 505E(a) states that the applicable <FONT STYLE="white-space:nowrap">3-year,</FONT> <FONT STYLE="white-space:nowrap">5-year,</FONT> or <FONT
STYLE="white-space:nowrap">7-year</FONT> exclusivity period for a QIDP-designated drug &#147;shall be extended by 5 years&#148; (GAIN Extension).<SUP STYLE="font-size:75%; vertical-align:top">13</SUP> Title VIII of the Food and Drug Administration
Safety and Innovation Act (FDASIA) (Public Law <FONT STYLE="white-space:nowrap">112-144),</FONT> entitled &#147;Generating Antibiotic Incentives Now,&#148; amended the FD&amp;C Act to add section 505E. This section was intended to address the public
health threat of antimicrobial drug resistance by incentivizing the development of new antibacterial and antifungal drugs for the treatment of serious or life-threatening infections.<SUP STYLE="font-size:75%; vertical-align:top">14</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term <I>QIDP</I> is defined in section 505E(g) of the FD&amp;C Act to mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">a drug . . . including an antibacterial or antifungal drug, for human use that&#151; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(1) acts on bacteria or fungi or on substances produced by such bacteria or fungi; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(2) is intended to treat a serious or life-threatening infection, including such an infection caused by&#151; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(A) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">12</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In 2016, in addressing the Agency&#146;s 2014 interpretation of the term <I>drug</I> in the relevant statutory
provisions governing <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity that established the eligibility of fixed-combination drug products comprising a new active moiety in combination with an old active moiety for <FONT
STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity, the U.S. District Court for the District of Columbia explained how the umbrella policy was a fundamental consideration in the application of this policy, and how the Agency&#146;s prior
interpretation that did not allow such fixed-combinations to avail of <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity ran contrary to the umbrella policy. See <I>Ferring Pharmaceuticals Inc., v. Burwell et al., </I>U.S. District Court
for the District of Columbia, No. CV <FONT STYLE="white-space:nowrap">15-0802</FONT> (RC), 2016 WL 4734333 (D.D.C. Sept. 9, 2016). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">13</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;505E(a) of the FD&amp;C Act. Specifically, the subsection states: &#147;If the Secretary approves
an application pursuant to section 505 for a drug that has been designated as a qualified infectious disease product under subsection (d), the <FONT STYLE="white-space:nowrap">4-</FONT> and <FONT STYLE="white-space:nowrap">5-year</FONT> periods
described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505, the <FONT STYLE="white-space:nowrap">3-year</FONT> periods described in clauses (iii)&nbsp;and (iv) of subsection (c)(3)(E) and clauses (iii)&nbsp;and (iv) of subsection
(j)(5)(F) of section 505, or the <FONT STYLE="white-space:nowrap">7-year</FONT> period described in section 527 [of the FD&amp;C Act (21 U.S.C. 360cc)], as applicable, shall be extended by 5 years.&#148; Furthermore, the GAIN Extension is in
addition to any extension of the <FONT STYLE="white-space:nowrap">6-month</FONT> pediatric exclusivity period under section 505A of the FD&amp;C Act. See section 505E(b) of the FD&amp;C Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">14</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Congressional Research Service Report R42680, <I>The Food and Drug Administration Safety and Innovation Act
(FDASIA, P.L. <FONT STYLE="white-space:nowrap">112-144)</FONT></I> (Feb 4, 2013), at 16 (&#147;FDASIA provides incentives for the development of certain new anti-infective drugs by providing an extended period of exclusivity.&#148;).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(B) qualifying pathogens listed by the Secretary under subsection (f).<SUP
STYLE="font-size:75%; vertical-align:top">15</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;505E(c) of the FD&amp;C Act (Limitations) lists the following limitations to the GAIN
Extension of section 505E(a): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subsection (a)&nbsp;does not apply to the approval of&#151; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(1) a supplement to an application under section 505(b) for any qualified infectious disease product for which an extension described in
subsection (a)&nbsp;is in effect or has expired; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(2) a subsequent application filed with respect to a product approved under section 505
for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(3) a product that does not meet the definition of a qualified infectious disease product under subsection (g)&nbsp;based upon its approved
uses; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(4) an application pursuant to section 351(a) of the Public Health Service Act. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FACTUAL BACKGROUND </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voquezna (NDA 215151) contains the single active moiety vonoprazan, which belongs to a new class of acid-inhibitory agents called potassium-competitive acid
blockers.<SUP STYLE="font-size:75%; vertical-align:top">16</SUP> The active moiety vonoprazan was first approved by FDA on May&nbsp;3, 2022, in the Voquezna Paks for the treatment of <I>Helicobacter pylori</I> (H.<I> pylori)</I> infection in adults.<SUP
STYLE="font-size:75%; vertical-align:top">17</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because vonoprazan had never been approved as an active moiety in any other application, FDA
recognized <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity for the Voquezna Paks. The Orange Book lists this exclusivity expiring on May&nbsp;3, 2027. Additionally, because the Voquezna Paks were designated as QIDPs, in part because
of their indication to treat <I>H. pylori</I> in adults,<SUP STYLE="font-size:75%; vertical-align:top">18</SUP> the <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity period recognized with respect to the new active moiety, vonoprazan,
was extended for an additional 5 years pursuant to the GAIN Extension of section 505E(a) of the FD&amp;C Act.<SUP STYLE="font-size:75%; vertical-align:top">19</SUP> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">15</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FDA&#146;s regulation at 21 CFR 317.2 provides the list of qualifying pathogens that have the potential to pose
a serious threat to public health. The Food and Drug Omnibus Reform Act of 2022 modified the original definition of <I>QIDP</I> to encompass drug products that &#147;[act] directly on bacteria or fungi or on substances produced by such bacteria or
fungi.&#148; This modified language is reproduced above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">16</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Clinical Reviewer/CDTL Summary Review for Voquezna (NDA 215151) at 8, dated Nov 1, 2023, available at
<U>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</U>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">17</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Voquezna Triple Pak and Voquezna Dual Pak Labeling, dated July&nbsp;31, 2024, available at
<U>https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215152s003,215153s003lbl.pdf</U>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">18</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May&nbsp;5, 2021, FDA granted QIDP designation for vonoprazan tablets, amoxicillin capsules, and
clarithromycin tablets <FONT STYLE="white-space:nowrap">(co-packaged)</FONT> for the treatment of <I>H. pylori</I> infection under investigational new drug application (IND) 143190 and for vonoprazan tablets and amoxicillin capsules <FONT
STYLE="white-space:nowrap">(co-packaged)</FONT> for the treatment of <I>H. pylori</I> infection under IND 144399. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">19</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The statutory limitations of section 505E(c) of the FD&amp;C Act to the GAIN Extension of section 505E(a) of
the FD&amp;C Act did not apply to the Voquezna Paks. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This NCE*GAIN exclusivity is listed in the Orange Book for the Voquezna Paks expiring on May&nbsp;3, 2032.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2023, FDA approved Voquezna (NDA 215151), a drug product containing the single active ingredient, and single active moiety,
vonoprazan. In addition to being approved for the treatment of <I>H. pylori</I> infection in adults (in combination with amoxicillin and clarithromycin), Voquezna is also approved for three indications: (1)&nbsp;for healing of all grades of erosive
esophagitis and relief of heartburn associated with erosive esophagitis in adults, (2)&nbsp;to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults, and (3)&nbsp;for the relief
of heartburn associated with nonerosive gastroesophageal reflux disease in adults.<SUP STYLE="font-size:75%; vertical-align:top">20</SUP> Voquezna was not designated as a QIDP.<SUP STYLE="font-size:75%; vertical-align:top">21</SUP> The Orange Book
currently lists <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity expiring on May&nbsp;3, 2027, for Voquezna, and does not reflect the NCE*GAIN exclusivity recognized for the Voquezna Paks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III. DISCUSSION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In your Petition, you argue that the
plain text of the statute and the longstanding umbrella policy interpretation require that FDA update Voquezna&#146;s Orange Book listing to reflect NCE*GAIN exclusivity.<SUP STYLE="font-size:75%; vertical-align:top">22</SUP> You assert that section
505E(a) of the FD&amp;C Act mandates the extension of the NCE exclusivity period by 5 years with respect to the active moiety vonoprazan.<SUP STYLE="font-size:75%; vertical-align:top">23</SUP> You additionally contend &#147;the GAIN Act extends [NCE
exclusivity] with its full scope and character retained,&#148; noting that Section&nbsp;505E(a) &#147;exten[ds] the duration&#148; of NCE exclusivity and does not change the scope or characteristics of the underlying exclusivity.<SUP
STYLE="font-size:75%; vertical-align:top">24</SUP> The Petition further argues that, under FDA&#146;s longstanding umbrella policy, <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity applies &#147;not just to the first approved drug
product containing no previously approved active moiety, but, with some [inapplicable] exceptions . . . to any other drug product developed that contains the same new active moiety as [in] the first drug product and that is approved during the [NCE
exclusivity] period.&#148;<SUP STYLE="font-size:75%; vertical-align:top">25</SUP> Therefore, Phathom believes the statute and the umbrella policy require FDA to recognize NCE*GAIN exclusivity for Voquezna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agree that Voquezna benefits from the NCE*GAIN exclusivity recognized for the Voquezna Paks. Recognition of NCE*GAIN exclusivity for Voquezna is consistent
with the statutory text of the GAIN provisions and the Agency&#146;s longstanding umbrella policy interpretation of NCE exclusivity and gives full effect to the NCE*GAIN exclusivity recognized for the QIDP-designated Voquezna Paks. While Voquezna is
not designated as a QIDP, the scope of NCE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">20</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Voquezna Labeling, dated Nov 1, 2023, available at
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215151s000lbl.pdf . </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">21</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For a drug product to be designated as a QIDP, a sponsor must submit a QIDP designation request. See section
505E(d)(1) of the FD&amp;C Act. The sponsor of Voquezna did not request QIDP designation for Voquezna. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">22</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Petition at 7. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">23</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Petition at 10. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">24</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Petition footnote 50 at 10. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">25</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Petition footnote 55 at 11, quoting the guidance for industry <I>New Chemical Entity Exclusivity Determinations
for Certain Fixed-Combination Drug Products&#148;</I> (October 2014) at 6 (Fixed-Combination NCE Guidance). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">exclusivity (or application of the bar clause) is determined by the active moiety, and Congress gave no
indication in the GAIN provisions that the NCE extension of section 505E(a) should not apply in this situation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Voquezna Benefits From the NCE*GAIN Exclusivity Recognized for the Voquezna Paks </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As detailed above in section II, the active moiety vonoprazan was first approved by FDA in the Voquezna Paks, resulting in the recognition of <FONT
STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity with respect to the active moiety vonoprazan. Because the Voquezna Paks were each designated as QIDPs, the <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity period recognized with
respect to the new active moiety, vonoprazan, was extended for an additional 5 years pursuant to section 505E(a) of the FD&amp;C Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;505E(a) of the FD&amp;C Act states that the applicable exclusivity periods &#147;shall be extended by 5 years&#148; for approved applications for
drugs designated as QIDPs. Section&nbsp;505E(a) is subject to section 505E(c), which specifies limitations where the GAIN Extension does not apply. None of the limitations set forth in section 505E(c) were implicated by the approval of the Voquezna
Paks, and therefore, section 505E(a) applied without limitation to extend the underlying NCE exclusivity recognized for the Voquezna Paks by 5 years.<SUP STYLE="font-size:75%; vertical-align:top">26</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The text of section 505E(a) extends the duration of the applicable exclusivity period recognized and section 505E does not otherwise limit or modify the scope
of the applicable exclusivity extended by section 505E(a). Although the limitations in section 505E(c) describe circumstances where an exclusivity extension under section 505E(a) is not available, when an exclusivity extension is recognized under
section 505E(a), these limitations do not modify its scope. In this case, <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity was the underlying exclusivity recognized for the Voquezna Paks and application of section 505E(a) extended this
underlying NCE exclusivity period, with the full scope of NCE exclusivity, by 5 additional years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the umbrella policy, NCE exclusivity applies
&#147;not just to the first unapproved drug product containing no previously approved active moiety, but . . . to any other drug product developed that contains the same new active moiety as in the first drug product and that is approved during the
[NCE exclusivity] period.&#148;<SUP STYLE="font-size:75%; vertical-align:top">27</SUP> Therefore, since section 505E(a) extends the applicable NCE exclusivity period, the <FONT STYLE="white-space:nowrap">5-year</FONT> extension would also apply to
any other drug product developed that contains the same new active moiety as the first approved drug product and that is approved during the NCE*GAIN period recognized for the Voquezna Paks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recognizing that Voquezna benefits from the NCE*GAIN period recognized for the Voquezna Paks represents a consistent interpretation of the word <I>drug</I> in
the NCE bar clause. Under the umbrella policy, the NCE bar clause restricts FDA&#146;s acceptance of a <FONT STYLE="white-space:nowrap">follow-on</FONT> (ANDA or </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">26</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We note that FDA is restricted by the NCE*GAIN exclusivity recognized for the Voquezna Paks from accepting or
approving applications for the active moiety vonoprazan for the duration of the NCE*GAIN exclusivity period recognized for the Voquezna Paks. Therefore, based on the text of the statute and the umbrella policy, the section 505E(c) limitations &#151;
including the 505E(c)(3) limitation &#151; have no bearing on the scope of NCE*GAIN exclusivity recognized for the Voquezna Paks and applied to Voquezna by application of the umbrella policy. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">27</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fixed-Combination NCE Guidance at 6. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">505(b)(2) NDA) application for a <I>drug substance,</I> or <I>active moiety,</I> that is covered by <FONT
STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity. As an application of the NCE bar clause, the umbrella policy blocks submission of any <FONT STYLE="white-space:nowrap">follow-on</FONT> drug product containing the protected active moiety,
irrespective of whether the <FONT STYLE="white-space:nowrap">follow-on</FONT> drug product relies on the drug product protected by NCE exclusivity. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recognition of NCE*GAIN Exclusivity for Voquezna Is Consistent With the Statutory Text of the GAIN
Provisions </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the GAIN provisions, FDA recognized NCE*GAIN exclusivity for the Voquezna Paks because they contained the NCE
vonoprazan, they were designated QIDPs, and none of the 505E(c) limitations applied. To give full effect to the NCE exclusivity recognized for the Voquezna Paks that was extended by GAIN, NCE*GAIN exclusivity must also be recognized for Voquezna.
This outcome is consistent with FDA&#146;s longstanding umbrella policy interpretation of the NCE bar clause, the purpose of which is to encourage further development and improvement of drugs containing the NCE without compromising the
innovator&#146;s exclusivity period by allowing the innovator to market different drugs containing the same active moiety and to benefit from the <FONT STYLE="white-space:nowrap">5-year</FONT> protection while doing so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in congressional deliberations, the GAIN title of FDASIA was intended to &#147;incentivize the development of new antibiotics, to treat, stop,
and conquer the superbugs . . . germs that are resistant to antibiotics that now exist.&#148;<SUP STYLE="font-size:75%; vertical-align:top">28</SUP> While Congress debated the scope of QIDP eligibility in an effort to target the incentive to
products that would treat serious or life-threatening infections,<SUP STYLE="font-size:75%; vertical-align:top">29</SUP> the available legislative record does not include any public debate or deliberation regarding the specific interaction between
the GAIN provisions and the umbrella policy interpretation of NCE exclusivity. Thus, although it is possible that Congress did not intend for drug products such as Voquezna to benefit from NCE*GAIN exclusivity, it is clear that Congress did intend
for drug products such as the Voquezna Paks to benefit from NCE*GAIN exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with the statutory text and FDA&#146;s longstanding umbrella
policy, which predated enactment of section 505E of the FD&amp;C Act, NCE exclusivity for Voquezna Paks covers Voquezna. Therefore, to ensure Voquezna Paks the full scope of their exclusivity for those drug products and, more specifically, for the
active moiety vonoprazan, Voquezna benefits from the remainder of the NCE exclusivity recognized for the Voquezna Paks, and the Orange Book will be updated to accurately reflect the <FONT STYLE="white-space:nowrap">10-year</FONT> period of nonpatent
NCE exclusivity in the Voquezna Orange Book listing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">28</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statement of Senator Blumenthal, Proceedings and Debates of the 112th Congress, Second Session (May 22, 2012)
158 Cong. Rec. S3396. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">29</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See, e.g., statement of Representative Waxman, Hearing Before the Subcommittee on Health of the Committee on
Energy and Commerce of the House of Representatives, 112th Congress, Second Session (Mar 8, 2012) at 118 (&#147;First, we need to make sure that we are only providing exclusivity for the kinds of drugs that will truly benefit the public health . . .
some believe that GAIN should be limited to new antibiotics for treating serious infections for which there is an unmet medical need.&#148;) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Docket No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA-2024-P-5703</FONT></FONT></FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONCLUSION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the reasons described above, the Petition is granted. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;Sincerely,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jacqueline A. </P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Corrigan-curay <FONT
STYLE="white-space:nowrap">-S</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;Jacqueline Corrigan-Curay, J.D., M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;Acting Director</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;Center for Drug Evaluation and
Research</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8195;Food and Drug Administration</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>phat-20250606.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/7/2025 12:03:20 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:phat="http://www.phathompharma.com/20250606"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.phathompharma.com/20250606"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20250606_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20250606_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>phat-20250606_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/7/2025 12:03:20 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>phat-20250606_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/7/2025 12:03:20 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="phat-20250606.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g941196g56z49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g941196g56z49.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Y 1 # 2(  A$! Q$!_\0
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M[,<'3]EA:TH1WLF>/CN'LLQM7VV+H1G+:[2;L?%'_#ACX)_\_7C3_P &4?\
M\:H_X<,?!/\ Y^O&G_@RC_\ C5?:]%=?^MN=?]!,_O.+_4W(_P#H$I_^ H^*
M#_P08^">/^/KQI_X,H__ (U7V%X%\(VWP_\ !>D:%9-*UEHME#86YE.7,<2!
M%W' R<*,\5JT5P8_.,=C4EBZKG;:[V/1R_)<!@'*6"HQIN6_*K7L%%%%>:>H
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001783183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PHATHOM PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4151574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Campus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Florham Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">742-8466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PHAT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d941196d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d941196d8k.htm">d941196d8k.htm</File>
    <File>phat-20250606.xsd</File>
    <File>phat-20250606_lab.xml</File>
    <File>phat-20250606_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d941196d8k.htm": {
   "nsprefix": "phat",
   "nsuri": "http://www.phathompharma.com/20250606",
   "dts": {
    "inline": {
     "local": [
      "d941196d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "phat-20250606.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "phat-20250606_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "phat-20250606_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-06-06_to_2025-06-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d941196d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-06-06_to_2025-06-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d941196d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.phathompharma.com//20250606/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-137094-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-137094-xbrl.zip
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MXV=&P=UA*B3L'FK:8N9^J*_6$#?:9VH95^K9JL)$=J@NPKH+'8R@^="EXS%
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MOA;Y3.4="Q<BY]7<PK;OHJO,2&],'+TK #W>@10SG2\WLQ3/%0%?%]QM''1
M!E(\A$/TN -<GJ>*N*S/?9,;;Q8[BP=D_C3.Y!!.A>PCC8].]()G7)GKK/H
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MN<W[G0!KW6HU@#;A',(GFG8OY2#U-=%@GP$L:.K"QL<A&N[,MW4B>]@9=TC
M7E?*((=KXYLA#"7*3;TX80'SA1,< Q'K=YT^V@B_7,EQ0C8[L;73$*W]O9VO
MM")'A[P"5J,\BDCV910;5!#/ *X:?TG 0ZY78HLL(<,/7N5<HXY][O$<YUOS
M N!;B3=0BY6AC5Y0Z*G6JM?:]9I75V9)'QD+8?G=.\8X5;]!0GUHA%_SE=RH
M9"1)#W3# ,$+WG%X22,A65.30\Z^PQW#5L(N,A6<GR O(.R2UI$,C? RHM@&
MC@&.$=.H=8>W0_5-83%HE-D(1PZBUD6RKU;NWQ#6,J@+^7WL10;7ZB/YLW7
M#*^'UIMLS::N83D- @L!BF. "RA^6#RTY9.8AZB(GA/D:H4YH.E[@3DL1K]>
M/V=^<.@&(0.C[I\ML;AW<-OUD'7"E@9AX 5]5%HE7M9YNG9],FO4O)O2[J'-
M BN#>PI(GT6KQ6"9[1<R3)#5WXNSNZ)A 8IFO@F,S"7;%KJ;U"T<ED\7\&F2
M%)!# 2N+"*D$#@IG?>!U/1\7EQM3S@D$2?*W/N-Z#Y#R<N(+MTH 8L@V5!IZ
M-_0G!UTX$1K6A6%W?51XB:G0(; OUEK7B?0LR/HHK.E5*ZI'--0X:%US%IU2
M#G)FE-2^]MB98N+R:]*_#[^+ODP1YBPQ[6M3>1W@G-FW _M!PYS"VY412P/Z
M.&!&\8%;0L?,P"Q:P,W*5I,NK9$$AD.W%IXA$K9X6[(C'.2GOJBY;\<Z4L\*
M_UW@V'G;:#] ^E5P/KF8L!*@UGGRA/ !S%8'CJ:\H5<4$QQY<:Q8&&XLBK;(
MN7*2,2\=DTQ.,$"OTFQ_\O?C%V[BJY@J!R@ZJ,D1*"LQVFAZ/=FCTU P#@_(
M!P,-G88B<]02ZFE9]TR@3!^J.S)6%*:%SD7X,SL8!2(I-S-;XI72I2Q3AI:4
M%CZP^I 6+Z_BQ97O:U&RW55D^PZF0]U/6(%ZH61QAKA7CD1 RD#5"&@3+R<X
M53UH.@RD7M86ZU$36LW*!/P3F':VE]NT<\47#P\/Z=&MU[;KM5-0%;S2>ZB$
M[Z#)T/'C, =)_*M>VZW7WMGM5"MV0].,0BLBFGIK+B\1Y6S&#79V66WPPO?+
MLFYPI]<4M;8M(Z FRB)"F7B 4"O^RFKGCE(PE;*J?$SSD%Y.QP.MG*DI%A,L
M":76*?PESZ>,.H&7,OP*MW$J!<C?LEF?3IE/9--Z_H I':^AXE+(:+FRKJZL
MJS^S=?41IK6CY36M%6UE&D3YI!VJ/I)#U0^RH:F(E-;^WC[J4.,P!A8=I;Y4
MBFW;LOO@:^QA8^FN%IK?4*IKDD$8($-&,L8VA^$M@H6WY,]LU%1C<\HL*I;6
M5:W8'N'&!O<0E[A[K#<QV>;"L63H%!C47P0)QU)0) PB:)DI<5'U\I52+RUL
MQQW"2N-%6O"GQ&L--&ET)#1>[@6UWS(B/LC/\#%^A>@@#J/7P,HDFL9" +6=
M.9T2#E+RSJ0_?[5BNUEFZGW)/)KV<LKO8Y^L#"]N?<-!^$XP2('-$0 P*=J<
MY,2:'?I S>N+EFFJ%00!R25WU/4&*<92. 0H,79$QM4\!)5#5U$2<OI]J<TU
M1%EDW XC[<2;<P2]MF*S[K(9*+];$*A\Z6!0VFU8(-&8WPV<* (:C:8X!"L*
MY4_ZY(+?S9UMG"H3N_VA"_N,T1B!?Y=)DGD*5_PS8K.-ZD>9-P@18T]^8]JF
MMDH<>+$C#?%Q%TWU[R=%PS#"_.0:]RTK=(SLS0\I,",FWB%Q'^,0 U_(I=J,
M (ZY1M(Q7*$\8(Q!,VNLVO#8,!$@6AIW5<16-L7NG65I4T9+U6/9,F1-,\TQ
MKR;02_+.3.SB9&##2YRW;A0ZO:FD1R-5I[&$X-AD1616C.7Q).YX2< @?L&T
M ??#D(@#@_VH&?9FF$JO>%K2/)'PNFH>3NQMPE6=J+(L<I&',97:$>]5>AG'
MPUA;G3G23R>XHLN]IH_8)A 0I:TS I\""VD8.IS&I&Q F:*JIH0K.;&R]Q;.
MV?35<&U"-=--X1&_O"E[-\A@*GL-7CJ/9SDQ$4*WS4R4@9V"V8S1I_0\373]
M$'CZ]0L9*J]#YO]&[K#,3XH!(E&9RS8+62ZS2A5,++E(D:>($T%K5J([S2Q:
M37+A6&R!]]0"9U0].7,8'W/3B&TKBDR+<7SJ\#DY+H"\.L3%?E)SK):=\_=C
M+ERF!T3M@UC+WB6&2&U[3O$85BOJ'#*;(N1W(FHFC& >(";G^C;1C8_;XNS<
M3K'63AT 6TS5@5[TD.TK&FC[L'\8\(#QM[ P'K"&3*J=V.Y'Z"%.DCC T(P_
M$5KK,(C6QS7(?)5LYIA9]AOL7$/"33@I.A<BE'C'*3SV*2D0U-MNFC"-H/Y$
MK)#Z54X;,P.T"I9FC".XIIG1$RZ0+3"-1_GI\>U$XZY-W+'UA6-9-Z=8MU>6
MO)\ HW^UW!C]1QN<:3P"G=G=$>\NQ=;>WNLM4?LM!?[1VB3GQ_TZJGWPQ?[K
M573?XM+9LA).I[>RU"TL"2[K9MJ'5QW6/3C7NYMO\=?]U4XO+.\MZTYW>JN]
M7%@R6];-+&K-$\@B:I/]D+#7-^IN_W+]%>$IQK?-T_$<\O"7F5+[5Y34";E2
MD1<&ZK%!]X)G.F%"\#<Y5L(3);".1S O-"-C&&L#1'P_:>"+K!4$8>"&E%X,
M';XC[X8T+'K ?KD7Q@C=81@6-)' 9X-DV!!1F":@X># <M'=]#Y*]@IAN!]>
M:HHVS'H4]C(_=:-^L:ITZ_E^/A.#5CJSO IY*\9(:38JJ,GHIM8JH0[IRYCU
M$7=(*<5"3)D6*\  NPAOG8B-@YCM1WM50=N)!ZWM9JF*9,&>F,_>HT/+&,O+
MJ]8]VG;>DE)<1;N?WG/3U&=<-7\[)XOME9/%RLEBMI/%\ZU=VW5!B0?V@=G>
MG@YH*J)JR-48Q+XCY.A?:6SRF<T"CBS@)@AMB*H<H!(V'I2_7Z9E[[% RBE^
MYI/F$2<V ;LT]EQ[#)&13YAE;'ML.IVFN**0K7EF-/T*Z3H^A5T\# WGD6C[
M7)0&)6%=!=/Y3%CP12)MQ2#,#/D%LB:$+H3KS@U3LMGUTXA!1*:)D511AMZ(
MAD]_0U,SG1Z ]*L5% % :"#C&"P1W&WJVYG&('7#HP%=YW+*O4-1-$Z$S,Z2
M6>Y-154@7D[E-P&J+TH,F8D='O8Q2QT%J,=ALV"F05,TIZS3R4N=7CA.]! ?
M9DZU)=87]KGXTOG:9U,Z3H,#HZJ5:1X)Q JF.1DXY69;VB,3\Z'#:-@)0P7/
MCRG"?8:E5"<7N#&B90.Z@PFD%/4><<JQ<BMOC7[Z;&DJ%_SJ#;9[PL1#=-C]
M)NU#8O@C&_1E<]!L(%G#<QSS0\;?3-@NV/_5X>F!+!^%=YI0V)TA[!-!Y;P
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M$HGD_/1[T@<9 +A'? =<Q?X ! B0BT@[T5&Y/X .M^O6<C&JI8_,2*H*,&1
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MB([$7LWG)\#-Z=,S!P/#@X$F,LP+JT13IK6=Q6F-+$E. G_^;R]TXPT?^]C
MMC:(KK?BS<WM!OVZC;_Z7;\Y[O57A/@PP7M9"?'"TG-VB99:'+D_ &4):0UO
M::/+Z(2"EA*(+H4RP505H_"[YWJ^CRX:SCA.?4D)+'I4&#P"%2$*1W>N9UZY
M7P^IN>$Z?/ -]JVG[:W3->^"IJ25:P8/O>!&QHDW4 6DRLNYU#KG)W71VMEN
M[6_242R?*\=!E$QW'K?&)YP3C!8&N[.]RBS[$.5N^<XB"ME6T2?+4%94<Z=8
MWQ;0D:N5B;>-"ZIMWBK *#^/ \&KE0/!RH'@1P6HDZYY?GSZ'W14"S4QE,^
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MA,PVA/P<M]+]5;O^6%X\^?CB_/CL4RYCW,M&:;PS^0Z=F%Q7#;A$,1N,(9G
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MLT5@N' O3OZ$#S]<_WYV^']02P,$%     @ ^X+&6OW%?UA  P  6PL  !$
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MO3B^ Z@-"N(W 7XWIZLW $V-\_UC3N__[>D@@9O^/Z^5<3C%[W/GW3_+9MU
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M7^C$DK\!4$L! A0#%     @ ^X+&6DNPU+P2%   %G$   X
M ( !     &0Y-#$Q.39D.&LN:'1M4$L! A0#%     @ ^X+&6LM6L13Z*P
MH@<! !$              ( !/A0  &0Y-#$Q.39D97@Y.3$N:'1M4$L! A0#
M%     @ ^X+&6OW%?UA  P  6PL  !$              ( !9T   '!H870M
M,C R-3 V,#8N>'-D4$L! A0#%     @ ^X+&6LX;]F!Z!@  N48  !4
M         ( !UD,  '!H870M,C R-3 V,#9?;&%B+GAM;%!+ 0(4 Q0    (
M /N"QEI":?L=Q 0  $DL   5              "  8-*  !P:&%T+3(P,C4P
A-C V7W!R92YX;6Q02P4&      4 !0!  0  >D\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d941196d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="phat-20250606.xsd" xlink:type="simple"/>
    <context id="duration_2025-06-06_to_2025-06-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2025-06-06</startDate>
            <endDate>2025-06-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-255">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-06-06_to_2025-06-06"
      id="Hidden_dei_EntityCentralIndexKey">0001783183</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-266">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-267">2025-06-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-268">PHATHOM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-269">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-270">001-39094</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-271">82-4151574</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-272">100 Campus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-273">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-274">Florham Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-275">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-276">07932</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-277">(877)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-278">742-8466</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-279">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-280">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-281">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-282">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-283">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-284">PHAT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-285">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-06-06_to_2025-06-06" id="ixv-286">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
